PGIM, an investment management company, released its “PGIM Jennison Health Sciences Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equities in the second quarter of 2025 experienced significant volatility, as the steep sell-off that initiated at the beginning of the quarter ultimately led to a strong recovery. The S&P 1500 Health Care Index declined 6.9% in the second quarter, underperforming the S&P 500’s 10.9% return. Health care providers & services, life sciences tools & services, biotechnology, and pharmaceuticals underperformed the Index in the quarter. While healthcare technology and medtech gained in the quarter. In June, the S&P 1500 Health Care Index (the Index) gained 1.9%, lagging the S&P 500, which advanced 5.1%. In addition, please check the fund’s top five holdings to know its best picks in 2025.
In its second-quarter 2025 investor letter, PGIM Jennison Health Sciences Fund highlighted stocks such as Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Neurocrine Biosciences, Inc. (NASDAQ:NBIX) engages in the development and marketing of pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders. The one-month return of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) was 5.56%, and its shares gained 26.52% of their value over the last 52 weeks. On September 24, 2025, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) stock closed at $146.67 per share, with a market capitalization of $14.547 billion.
PGIM Jennison Health Sciences Fund stated the following regarding Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in its second quarter 2025 investor letter:
“Neurocrine Biosciences, Inc. (NASDAQ:NBIX) the continued recovery of Neurocrine post what increasingly looks like a guidance mistake rather than an operational issue, as they reported stronger than expected 1Q results and continue to sound optimistic about 2Q as well.”
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is not on our list of 30 Most Popular Stocks Among Hedge Funds. According to our database, 59 hedge fund portfolios held Neurocrine Biosciences, Inc. (NASDAQ:NBIX) at the end of the second quarter, down from 63 in the previous quarter. While we acknowledge the potential of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
finance.yahoo.com
#Optimistic #Neurocrine #Biosciences #NBIX
